Andrew Whiteley

Andrew Whiteley is a seasoned executive in the life sciences sector with extensive experience in business development, technology transfer, and strategic consulting. Since May 2025, Andrew has served as a Board Member at the Nadia Valsecchi Foundation and holds the position of VP Business Development and Technology Transfer at Cold Spring Harbor Laboratory, where Andrew has worked since March 2016. Andrew also serves as an Executive in Residence and holds various board positions, including Board Director for DepYmed and Certerra, as well as Executive Chairman for Marvel Genomics. Previous roles include Interim CEO for Clarapath, Director for Certerra Inc., and Director of Scientific and Medical Programs at The Lustgarten Foundation. Andrew’s earlier career included executive positions at Enzo Biochem, Vitra Biosystems, and Amersham Biosciences, backed by a BSc in Biochemistry and Chemistry from the University of Nottingham and a Global BioExecutive Program credential from the Haas School of Business at UC Berkeley.